Related Experiment Video

Updated: Jun 20, 2026

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

Tipifarnib in the treatment of acute myeloid leukemia

Xavier Thomas1, Mohamed Elhamri

  • 1Hematology, Edouard Herriot Hospital, Lyon, France.

Biologics : Targets & Therapy
|August 27, 2009
PubMed

Insights

Farnesyltransferase inhibitors (FTIs) show potential in treating acute myeloid leukemia (AML). Tipifarnib, an FTI, demonstrated clinical responses but requires further research for optimal AML therapy, possibly in combination treatments.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Farnesyltransferase inhibitors (FTIs) represent a novel class of anticancer agents.
  • The precise anti-tumorigenic mechanisms of FTIs are not fully elucidated.
  • FTIs function by inhibiting the farnesylation of various target proteins.

Purpose of the Study:

  • To evaluate the efficacy of tipifarnib, a non-peptidomimetic competitive FTI, in preclinical models and clinical settings for acute myeloid leukemia (AML).
  • To understand the potential role and limitations of tipifarnib as a single agent in AML treatment.
  • To identify strategies for optimizing FTI therapy in AML patients, including combination approaches.

Main Methods:

  • Preclinical evaluation of tipifarnib in leukemia models.
  • Clinical trials assessing tipifarnib in adult patients with refractory/relapsed AML and newly diagnosed poor-risk AML.
  • Ongoing trials investigating combinations of tipifarnib with cytotoxic agents.

Main Results:

  • Tipifarnib demonstrated significant potency against leukemic cells in preclinical studies.
  • Clinical responses were observed in adult AML patients, though less than anticipated.
  • Tipifarnib may hold importance as a single agent in specific patient subgroups.

Conclusions:

  • Tipifarnib exhibits activity in AML, but its therapeutic impact as a monotherapy requires further investigation.
  • Optimizing FTI therapy for AML necessitates a deeper understanding of its mechanisms and patient selection.
  • Combination therapies involving tipifarnib and cytotoxics are a promising avenue for future AML treatment strategies.
Keywords:
acute myeloid leukemiafarnesyltransferase inhibitorprognosistargeted therapytipifarnib

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Related Concept Videos

Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...